DexCom, Inc. (DXCM)
$
68.29
+0.55 (0.81%)
Key metrics
Financial statements
Free cash flow per share
1.5794
Market cap
26.5 Billion
Price to sales ratio
6.5636
Debt to equity
1.2027
Current ratio
1.4671
Income quality
1.7173
Average inventory
564.5 Million
ROE
0.2630
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
DexCom, Inc. is a medical device company that specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems globally. The company earned an interest income of $134,200,000.00 showcasing its financial investments. Its products are utilized by individuals with diabetes and healthcare providers alike, featuring systems such as the DexCom G6, an integrated CGM system for effective diabetes management. The earnings before interest, taxes, depreciation, and amortization (EBITDA) is $840,699,947.00 a key indicator of the company's operational profitability. The company's product range also includes the Dexcom Real-Time API, which allows third-party developers to integrate real-time CGM data into digital health applications, and the Dexcom ONE, designed to eliminate the need for finger-stick blood glucose testing for diabetes treatment decisions. Additionally, DexCom Share provides remote monitoring capabilities. The company recorded an operating income of $600,000,000.00 reflecting its earnings from core operations, and the earnings per share (EPS) is reported at $1.42 indicating the company's profitability on a per-share basis. With a weighted average number of shares outstanding of 404,624,602.00 the company's shareholder base is highlighted, demonstrating its broad market engagement. The candidate for new offerings includes the next-generation Dexcom G7 CGM system, which is anticipated to enhance its product lineup. Furthermore, DexCom, Inc. has established a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop innovative blood-based or interstitial glucose monitoring products, marking an exciting expansion for the firm. In terms of market positioning, the stock is reasonably priced at $67.27 appealing to a broad range of investors. The stock exhibits a high average trading volume of 3,935,741.00 indicating strong liquidity in the market. With a mid-range market capitalization of $26,685,819,880.00 the company is a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Additionally, DexCom, Inc. belongs to the Healthcare sector, driving innovation and growth, which positions the company favorably for future advancements and investor interest.
What is DexCom, Inc. (DXCM)'s stock forecast?
Analysts predict DexCom, Inc. stock to fluctuate between $62.34 (low) and $141.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is DexCom, Inc.'s market capitalization?
As of 2025-04-01, DexCom, Inc.'s market cap is $26,685,819,880, based on 390,772,000 outstanding shares.
How does DexCom, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., DexCom, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy DexCom, Inc. (DXCM) stock?
To buy DexCom, Inc. (DXCM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DXCM. Place an order (Market, Limit, etc.).
What is the best time to invest in DexCom, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did DexCom, Inc. perform in the last earnings report?
Revenue: $4,033,000,000 | EPS: $1.42 | Growth: -1.39%.
Where can I find DexCom, Inc.'s investor relations reports?
Visit https://www.dexcom.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for DexCom, Inc.?
You can explore historical data from here
What is the all-time high and low for DexCom, Inc. stock?
All-time high: $164.86 (2021-11-18) | All-time low: $62.34 (2024-07-26).
What are the key trends affecting DexCom, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre.
businesswire.com
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable in.
zacks.com
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
reuters.com
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down nearly 7% after the bell.
seekingalpha.com
DexCom, Inc. (NASDAQ:DXCM ) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of Investor Relations Conference Call Participants Jayson Bedford - Raymond James Jayson Bedford Good morning. Welcome to the 46th Annual Raymond James Institutional Investors Conference.
fool.com
The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth stocks to own for the long term. As these companies steadily grow their revenue and profits, they become more valuable, and investors will be willing to pay more for them.
benzinga.com
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
benzinga.com
DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.
seekingalpha.com
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Steve Lichtman - Oppenheimer Issie Kirby - Redburn-Atlantic Michael Polark - Wolfe Research Patrick Wood - Morgan Stanley Sam Eiber - BTIG Mike Kratky - Leerink Operator Thank you for standing by.
See all news
